ライフサイエンスコーパス: acquired immunodeficiency syndrome

1 inhibitors against HIV, the culprit of AIDS (acquired immunodeficiency syndrome).

2 ed ART; 5 patients died (unrelated to HIV or acquired immunodeficiency syndrome).

3 compromised patients with cancer or advanced acquired immunodeficiency syndrome.

4 (>/=2 symptoms), and deaths were ascribed to acquired immunodeficiency syndrome.

5 al failure, and human immunodeficiency virus/acquired immunodeficiency syndrome.

6 voirs for viral persistence in patients with acquired immunodeficiency syndrome.

7 carinii DHPS mutations in 107 patients with acquired immunodeficiency syndrome.

8 as been approved by the FDA for treatment of acquired immunodeficiency syndrome.

9 larly in the context of immunodeficiency and acquired immunodeficiency syndrome.

10 n immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome.

11 iciency virus infection and delayed onset of acquired immunodeficiency syndrome.

12 regenerative states, immune cytopenias, and acquired immunodeficiency syndrome.

13 using SSRI treatment adjunctively in HIV and acquired immunodeficiency syndrome.

14 ts have been described only in patients with acquired immunodeficiency syndrome.

15 on opportunistic infections in patients with acquired immunodeficiency syndrome.

16 ing to the vascular injury syndromes seen in acquired immunodeficiency syndrome.

17 rus infection, particularly in patients with acquired immunodeficiency syndrome.

18 h cytomegalovirus-associated esophagitis and acquired immunodeficiency syndrome.

19 er nonmalignant CNS lesions in patients with acquired immunodeficiency syndrome.

20 h human immunodeficiency virus (HIV) but not acquired immunodeficiency syndrome.

21 cell counts <350 cells/mm(3) and 2 (7%) had acquired immunodeficiency syndrome.

22 ciency virus (SIV)-infected macaque model of acquired immunodeficiency syndrome.

23 in the relative risk of death related to the acquired immunodeficiency syndrome (0.73; 95 percent con

24 5,321 person-years, 268 of 614 men incurred acquired immunodeficiency syndrome, 49 died, and 90 were

25 uman immunodeficiency virus infection or the acquired immunodeficiency syndrome (7 percent each).

26 Fifty-nine percent had the acquired immunodeficiency syndrome according to the case

27 load after infection and 5-year incidence of acquired immunodeficiency syndrome, adjusting for (conti

28 study, baseline plasma from 619 persons with acquired immunodeficiency syndrome (AIDS) (median CD4+ l

29 fect of injection drug use on 6-year risk of acquired immunodeficiency syndrome (AIDS) after initiati

30 To investigate the validity of self-reported acquired immunodeficiency syndrome (AIDS) among women en

31 ne their associations with incident clinical acquired immunodeficiency syndrome (AIDS) and CD4+ T cel

32 iciency virus (HIV)-infected men at risk for acquired immunodeficiency syndrome (AIDS) and followed b

33 gnificant reductions in the incidence of the acquired immunodeficiency syndrome (AIDS) and in mortali

34 T) has dramatically reduced the incidence of acquired immunodeficiency syndrome (AIDS) and increased

35 pontine myelinolysis), infections [malaria, acquired immunodeficiency syndrome (AIDS) and infection

36 es suggest a correlation between severity of acquired immunodeficiency syndrome (AIDS) and selenium d

37 Time to development of acquired immunodeficiency syndrome (AIDS) and time to de

38 In 1981, the acquired immunodeficiency syndrome (AIDS) appeared insid

39 Encephalitis and dementia associated with acquired immunodeficiency syndrome (AIDS) are characteri

40 ections of the biliary tree in patients with acquired immunodeficiency syndrome (AIDS) are well known

41 return visit to the clinic and being free of acquired immunodeficiency syndrome (AIDS) at enrollment.

42 ed 13 years or older who were diagnosed with acquired immunodeficiency syndrome (AIDS) between Januar

43 A total of 1600 participants with acquired immunodeficiency syndrome (AIDS) but without CM

44 mimic a clinical trial to assess the risk of acquired immunodeficiency syndrome (AIDS) by timing of t

45 quantify the cumulative survival benefits of acquired immunodeficiency syndrome (AIDS) care in the Un

46 ods for estimating the prevented fraction of acquired immunodeficiency syndrome (AIDS) cases attribut

47 lor represent an increasing proportion of US acquired immunodeficiency syndrome (AIDS) cases, few res

48 cterized for certain biliary diseases, e.g., acquired immunodeficiency syndrome (AIDS) cholangiopathy

49 Biliary cryptosporidiosis is associated with acquired immunodeficiency syndrome (AIDS) cholangiopathy

50 ession on CD8(+) T lymphocytes may relate to acquired immunodeficiency syndrome (AIDS) clinical progr

51 ficiency virus (HIV) infections and averting acquired immunodeficiency syndrome (AIDS) deaths in the

52 Declines in the number of acquired immunodeficiency syndrome (AIDS) deaths were fi

53 tions occurred in one patient (25%), all non-acquired immunodeficiency syndrome (AIDs) defining.

54 (HIV)-infected brain in relationship to the acquired immunodeficiency syndrome (AIDS) dementia compl

55 Progressive immune dysfunction and the acquired immunodeficiency syndrome (AIDS) develop in mos

56 human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome (AIDS) epidemic has g

57 se to the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) epidemic is th

58 The effect of the acquired immunodeficiency syndrome (AIDS) epidemic on wo

59 Containment of the acquired immunodeficiency syndrome (AIDS) epidemic will

60 (HIV) vaccine is critical to end the global acquired immunodeficiency syndrome (AIDS) epidemic, but

61 Early in the acquired immunodeficiency syndrome (AIDS) epidemic, epid

62 networks in predicting rapid progression to acquired immunodeficiency syndrome (AIDS) for patients w

63 genes into both T cells and macrophages for acquired immunodeficiency syndrome (AIDS) gene therapy.

64 In contrast, persons with established acquired immunodeficiency syndrome (AIDS) had a signific

65 ndidate genes for stem cell gene therapy for acquired immunodeficiency syndrome (AIDS) has been limit

66 Persons with acquired immunodeficiency syndrome (AIDS) have a higher

67 ons with cytomegalovirus (CMV) retinitis and acquired immunodeficiency syndrome (AIDS) have required

68 r and was mainly due to the emergence of the acquired immunodeficiency syndrome (AIDS) in 25- to 64-y

69 eficiency virus type 1 (HIV-1), the cause of acquired immunodeficiency syndrome (AIDS) in humans, eff

70 SIVsm from sooty mangabeys, are the cause of acquired immunodeficiency syndrome (AIDS) in humans.

71 virus type 1 (HIV-1), the etiologic agent of acquired immunodeficiency syndrome (AIDS) in humans.

72 ently have focused on access to treatment of acquired immunodeficiency syndrome (AIDS) in poor, sever

73 mmunodeficiency virus (HIV) infection or the acquired immunodeficiency syndrome (AIDS) in sub-Saharan

74 n immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) in the federal

75 's Health Study (SFMHS); 268 men without the acquired immunodeficiency syndrome (AIDS) in the SFMHS w

76 iruses, however, SIVs do not generally cause acquired immunodeficiency syndrome (AIDS) in their natur

77 activation is a key factor in progression to acquired immunodeficiency syndrome (AIDS) in untreated H

78 Acquired immunodeficiency syndrome (AIDS) is principally

79 l leukoencephalopathy (PML) complicating the acquired immunodeficiency syndrome (AIDS) is typically i

80 As people with acquired immunodeficiency syndrome (AIDS) live longer, t

81 uals with a high viral set point progress to acquired immunodeficiency syndrome (AIDS) more rapidly t

82 To understand recent temporal trends in acquired immunodeficiency syndrome (AIDS) mortality in t

83 lative risk (RR) for clinical progression to acquired immunodeficiency syndrome (AIDS) of 1.66 (95% c

84 idemic of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) on demand for

85 gosity of class I loci (A, B, and C) delayed acquired immunodeficiency syndrome (AIDS) onset among pa

86 c millimeter or until the development of the acquired immunodeficiency syndrome (AIDS) or another con

87 hly active antiretroviral therapy on time to acquired immunodeficiency syndrome (AIDS) or death in 1,

88 Rates of acquired immunodeficiency syndrome (AIDS) or death on su

89 iretroviral therapy initiation with incident acquired immunodeficiency syndrome (AIDS) or death while

90 ve antiretroviral therapy (HAART) on time to acquired immunodeficiency syndrome (AIDS) or death, the

91 re urgently needed to curb the growth of the acquired immunodeficiency syndrome (AIDS) pandemic and u

92 erapeutic strategies that aim to contain the acquired immunodeficiency syndrome (AIDS) pandemic.

93 The hallmark of acquired immunodeficiency syndrome (AIDS) pathogenesis i

94 V-infected populations compared with similar acquired immunodeficiency syndrome (AIDS) patients in th

95 CSF samples from 15 acquired immunodeficiency syndrome (AIDS) patients with

96 This study reports the surgical outcomes of acquired immunodeficiency syndrome (AIDS) patients with

97 entify cancers that occur at higher rates in acquired immunodeficiency syndrome (AIDS) patients, the

98 tivation and drives systemic inflammation in acquired immunodeficiency syndrome (AIDS) patients.

99 es persistent skin neoplasms in children and acquired immunodeficiency syndrome (AIDS) patients.

100 fection in a new host is a critical goal for acquired immunodeficiency syndrome (AIDS) research.

101 tion analysis of five cohorts of people with acquired immunodeficiency syndrome (AIDS) revealed that

102 Most acquired immunodeficiency syndrome (AIDS) service provid

103 ococcal disease incidence among persons with acquired immunodeficiency syndrome (AIDS) since the intr

104 reduced in alveolar macrophages and PMN from acquired immunodeficiency syndrome (AIDS) subjects, we i

105 The authors assessed temporal trends in acquired immunodeficiency syndrome (AIDS) survival for 1

106 age is associated with markedly enhanced HIV/acquired immunodeficiency syndrome (AIDS) susceptibility

107 iciency virus (HIV) among cases who obtained acquired immunodeficiency syndrome (AIDS) through hetero

108 nctively associated with communication about acquired immunodeficiency syndrome (AIDS) through social

109 esign, the authors compared 1,642 women with acquired immunodeficiency syndrome (AIDS) to 8,443 uninf

110 ted from monkeys with acute SIV infection or acquired immunodeficiency syndrome (AIDS) underwent norm

111 impact of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) versus other l

112 ed States-based natural-history cohorts with acquired immunodeficiency syndrome (AIDS) were genotyped

113 megalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) who are receiv

114 gous state, SDF1-3'A/3'A delays the onset of acquired immunodeficiency syndrome (AIDS), according to

115 affects about 4 percent of patients with the acquired immunodeficiency syndrome (AIDS), and survival

116 se to cryptosporidiosis in patients with the acquired immunodeficiency syndrome (AIDS), and went on t

117 tomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS), but it does n

118 redicts the likelihood of progression to the acquired immunodeficiency syndrome (AIDS), but the relat

119 ere followed from seroconversion to incident acquired immunodeficiency syndrome (AIDS), death, or the

120 ncy virus type 1 (HIV-1), the cause of human acquired immunodeficiency syndrome (AIDS), is a zoonotic

121 ciency virus type 1 (HIV-1) infection to the acquired immunodeficiency syndrome (AIDS), it appears th

122 udy was to measure, as a model of wasting in acquired immunodeficiency syndrome (AIDS), longitudinal

123 eases included in the case definition of the acquired immunodeficiency syndrome (AIDS), non-AIDS-defi

124 In addition to acquired immunodeficiency syndrome (AIDS), persons infec

125 reduced prevalence and mortality induced by acquired immunodeficiency syndrome (AIDS), provided the

126 inment of deaths among people diagnosed with acquired immunodeficiency syndrome (AIDS), the authors d

127 ctives on human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), tuberculosis

128 and immune activation predict progression to acquired immunodeficiency syndrome (AIDS), we evaluated

129 pe SIV infection in macaques leads to simian Acquired Immunodeficiency Syndrome (AIDS), which does no

130 ly antiretroviral therapy, which can prevent acquired immunodeficiency syndrome (AIDS)-associated eve

131 Patients with acquired immunodeficiency syndrome (AIDS)-associated non

132 virus (SIV)-infected macaques as a model of acquired immunodeficiency syndrome (AIDS)-associated P.

133 The acquired immunodeficiency syndrome (AIDS)-causing lentiv

134 asures were death, the occurrence of a first acquired immunodeficiency syndrome (AIDS)-defining condi

135 Histoplasmosis is among the main acquired immunodeficiency syndrome (AIDS)-defining condi

136 carinii pneumonia was the initial (and only) acquired immunodeficiency syndrome (AIDS)-defining diagn

137 re divided by disease severity defined as an acquired immunodeficiency syndrome (AIDS)-defining event

138 Ten individuals developed acquired immunodeficiency syndrome (AIDS)-defining event

139 definition of LTF on estimated rates of LTF, acquired immunodeficiency syndrome (AIDS)-defining event

140 e antiretroviral therapy (HAART) on multiple acquired immunodeficiency syndrome (AIDS)-defining illne

141 did not have a new (previously undiagnosed) acquired immunodeficiency syndrome (AIDS)-defining illne

142 nemia was 36.9% for persons with one or more acquired immunodeficiency syndrome (AIDS)-defining oppor

143 follow-up; all were antiretroviral-naive and acquired immunodeficiency syndrome (AIDS)-free prior to

144 o identify CD4(+) levels associated with the acquired immunodeficiency syndrome (AIDS)-free time equi

145 The acquired immunodeficiency syndrome (AIDS)-protective che

146 We assessed non-liver-related non-acquired immunodeficiency syndrome (AIDS)-related (NLR-N

147 from eight HCV-infected patients who died of acquired immunodeficiency syndrome (AIDS)-related compli

148 venues for investigating the pathogenesis of acquired immunodeficiency syndrome (AIDS)-related cytope

149 To determine whether microbiologic cure of acquired immunodeficiency syndrome (AIDS)-related dissem

150 and to determine the role that a hospital's acquired immunodeficiency syndrome (AIDS)-related experi

151 munodeficiency virus (HIV) have shifted from acquired immunodeficiency syndrome (AIDS)-related illnes

152 e 1 pilot study of IL-12 in 32 patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi

153 ARL (acquired immunodeficiency syndrome (AIDS)-related lympho

154 osing event in the early pathogenesis of the acquired immunodeficiency syndrome (AIDS)-related lympho

155 ffect of time-varying incident TB on time to acquired immunodeficiency syndrome (AIDS)-related mortal

156 in Kaposi's sarcoma (KS), as well as in some acquired immunodeficiency syndrome (AIDS)-related non-Ho

157 emonstrated that prior to the development of acquired immunodeficiency syndrome (AIDS)-related pulmon

158 mic" pediatric Burkitt's lymphomas (BL), two acquired immunodeficiency syndrome (AIDS)-related type I

159 the development of a preventive vaccine for acquired immunodeficiency syndrome (AIDS).

160 ficiency virus (SIV) very rarely progress to acquired immunodeficiency syndrome (AIDS).

161 proportional increases in incidence rates of acquired immunodeficiency syndrome (AIDS).

162 macular degeneration (AMD) in patients with acquired immunodeficiency syndrome (AIDS).

163 mon opportunistic infection of patients with acquired immunodeficiency syndrome (AIDS).

164 cterial infection in untreated patients with acquired immunodeficiency syndrome (AIDS).

165 function and its predictors in children with acquired immunodeficiency syndrome (AIDS).

166 may cause chronic diarrhea in patients with acquired immunodeficiency syndrome (AIDS).

167 the main target for design of drugs against acquired immunodeficiency syndrome (AIDS).

168 ied cocaine as a cofactor for development of acquired immunodeficiency syndrome (AIDS).

169 trointestinal disease are common features of acquired immunodeficiency syndrome (AIDS).

170 galovirus retinitis in 160 patients with the acquired immunodeficiency syndrome (AIDS).

171 ant declines in morbidity and mortality from acquired immunodeficiency syndrome (AIDS).

172 ents with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome (AIDS).

173 o be a cofactor in the immunopathogenesis of acquired immunodeficiency syndrome (AIDS).

174 mal viral infectivity and the progression to acquired immunodeficiency syndrome (AIDS).

175 atment of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS).

176 t complication of pneumonia in patients with acquired immunodeficiency syndrome (AIDS).

177 ollowing adoptive transfer to a patient with acquired immunodeficiency syndrome (AIDS).

178 sexually transmitted diseases, including the acquired immunodeficiency syndrome (AIDS).

179 er viral loads and more rapid progression to acquired immunodeficiency syndrome (AIDS).

180 s of opportunistic infections related to the acquired immunodeficiency syndrome (AIDS).

181 e and non-Hodgkin's lymphomas related to the acquired immunodeficiency syndrome (AIDS).

182 morbidity and mortality associated with the acquired immunodeficiency syndrome (AIDS).

183 groups: adults and children with and without acquired immunodeficiency syndrome (AIDS).

184 HIV infection, is a principal driver of the acquired immunodeficiency syndrome (AIDS).

185 ersistent infections in humans which lead to acquired immunodeficiency syndrome (AIDS).

186 tomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS).

187 of morbidity and mortality in patients with acquired immunodeficiency syndrome (AIDS).

188 advanced human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS).

189 driving force of CD4(+) T-cell depletion and acquired immunodeficiency syndrome (AIDS).

190 actor for HIV-1 infection and progression to acquired immunodeficiency syndrome (AIDS).

191 of the stomach and esophagus in people with acquired immunodeficiency syndrome (AIDS).

192 th species-specific SIVs, but do not develop acquired immunodeficiency syndrome (AIDS).

193 infection since the earliest recognition of acquired immunodeficiency syndrome (AIDS).

194 Five patients had acquired immunodeficiency syndrome (AIDS); one had commo

195 ders, and infectious diseases (excluding the acquired immunodeficiency syndrome [AIDS]), many of whic

196 interferon (rIFN)- gamma 1b in patients with acquired immunodeficiency syndrome and acute cryptococca

197 from culture isolates from 87 patients with acquired immunodeficiency syndrome and CMV retinitis who

198 rnet resistance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis.

199 they had an increased risk of progression to acquired immunodeficiency syndrome and death, a relation

200 sis is classically reported in patients with acquired immunodeficiency syndrome and emerged as a caus

201 regular alcohol consumption (one of whom had acquired immunodeficiency syndrome and hepatitis B), one

202 and clinical parameters among patients with acquired immunodeficiency syndrome and histoplasmosis in

203 ts with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious

204 rden created by human immunodeficiency virus/acquired immunodeficiency syndrome and other infectious

205 rates of incarceration and reported cases of acquired immunodeficiency syndrome and syphilis were wea

206 to neonatal infection, transplantation, and acquired immunodeficiency syndrome-associated CMV diseas

207 The acquired immunodeficiency syndrome-associated lymphoma A

208 reducing the disease burden in patients with acquired immunodeficiency syndrome-associated tuberculos

209 Records of people diagnosed with acquired immunodeficiency syndrome between 1993 and 2007

210 eme Court's first case involving HIV and the acquired immunodeficiency syndrome, Bragdon v Abbott, ad

211 However, the acquired immunodeficiency syndrome, breast cancer, diabe

212 TB accelerates acquired immunodeficiency syndrome by increasing human i

213 to develop immunotherapeutic strategies for acquired immunodeficiency syndrome capable of activating

214 he basic package of services provided by HIV/acquired immunodeficiency syndrome care and treatment pr

215 In patients with sclerosing cholangitis and acquired immunodeficiency syndrome cholangiopathy, MRCP

216 (International Maternal Pediatric Adolescent Acquired Immunodeficiency Syndrome Clinical Trials [IMPA

217 s were enrolled at 28 sites of the Pediatric Acquired Immunodeficiency Syndrome Clinical Trials Group

218 men who were participants in the Multicenter Acquired Immunodeficiency Syndrome Cohort Study for GBV-

219 en-group differences in the incidence of the acquired immunodeficiency syndrome, death, or serious ad

220 00 x 10(6)/L and 549 x 10(6)/L without prior acquired immunodeficiency syndrome-defining conditions r

221 ficantly higher for patients without a prior acquired immunodeficiency syndrome-defining illness and

222 tion, whereas patients who developed another acquired immunodeficiency syndrome-defining illness did

223 s were used to determine predictors of a new acquired immunodeficiency syndrome-defining illness or d

224 nts with Medicaid, and patients with a prior acquired immunodeficiency syndrome-defining illness were

225 infection and CIN, and cervical cancer is an acquired immunodeficiency syndrome-defining illness.

226 r, and 65 percent of the patients had had an acquired immunodeficiency syndrome-defining illness.

227 ive multifocal leukoencephalopathy (PML), an acquired immunodeficiency syndrome-defining illness.

228 es brain function and presents clinically as acquired immunodeficiency syndrome dementia complex (ADC

229 vanced immunodeficiency, all 4 subjects with acquired immunodeficiency syndrome dementia complex had

230 tors for NTS, including autoimmune diseases, acquired immunodeficiency syndrome, diabetes, cirrhosis,

231 The proportion of acquired immunodeficiency syndrome diagnoses in which wa

232 Having an acquired immunodeficiency syndrome diagnosis or multiple

233 ntigen genetic association with HIV-1 and/or acquired immunodeficiency syndrome disease progression i

234 fies clinical presentation in the era of the acquired immunodeficiency syndrome epidemic.

235 rus type 1 (HIV-1) and those affected by the acquired immunodeficiency syndrome epidemic.

236 ted from 2 ALIVE scientists and an expert in acquired immunodeficiency syndrome epidemiology about th

237 potential therapeutic target to prevent non-acquired immunodeficiency syndrome events.

238 r patients attending a county outpatient HIV/acquired immunodeficiency syndrome facility were referre

239 1984-2008, regarding estimation of long-term acquired immunodeficiency syndrome-free survival to demo

240 ciency virus (HIV)-infected subjects without acquired immunodeficiency syndrome have a high frequency

241 Although the incidence of and mortality from acquired immunodeficiency syndrome have declined recentl

242 orbid human immunodeficiency virus infection/acquired immunodeficiency syndrome (HIV/AIDS) (OR = 4.27

243 h has scaled-up human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) care and t

244 Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) is one of

245 ch as diabetes, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), arthritis

246 illimeter or if an illness indicative of the acquired immunodeficiency syndrome (i.e., an AIDS-defini

247 t the LP-BM5 murine leukemia virus causes an acquired immunodeficiency syndrome in C57BL/6 mice (MAID

248 etermine the feasibility of gene therapy for acquired immunodeficiency syndrome in individuals alread

249 rculosis is often the first manifestation of acquired immunodeficiency syndrome in patients infected

250 fection causes an AIDS-like syndrome--murine acquired immunodeficiency syndrome--in C57B1/6 mice and

251 gene therapy strategies for diseases such as acquired immunodeficiency syndrome is limited.

252 HIV-2, a human pathogen that causes acquired immunodeficiency syndrome, is distinct from the

253 type 1 reduces the mortality of persons with acquired immunodeficiency syndrome, it does not eliminat

254 cted injection drug users recruited into the Acquired Immunodeficiency Syndrome Link to Intravenous E

255 In nonhuman primate models of acquired immunodeficiency syndrome, live attenuated lent

256 man immunodeficiency virus infection and the acquired immunodeficiency syndrome, medical malpractice,

257 Deaths from acquired immunodeficiency syndrome occurred exclusively

258 to initiate therapy prior to progression to acquired immunodeficiency syndrome or death by both meas

259 ts of dropout, the weighted hazard ratio for acquired immunodeficiency syndrome or death comparing us

260 ly active antiretroviral therapy on incident acquired immunodeficiency syndrome or death, the authors

261 active antiretroviral therapy, 211 developed acquired immunodeficiency syndrome or died, and 173 drop

262 r patients with human immunodeficiency virus/acquired immunodeficiency syndrome or substance abuse (f

263 0, CI 0.28-0.57) and increased with comorbid acquired immunodeficiency syndrome (OR 4.52, CI 3.01-6.7

264 ings has begun to mitigate the impact of the acquired immunodeficiency syndrome pandemic.

265 anciclovir has become increasingly common in acquired immunodeficiency syndrome patients but has only

266 the spinal cord dorsal horn (SDH) from HIV-1/acquired immunodeficiency syndrome patients who develope

267 g patients with human immunodeficiency virus/acquired immunodeficiency syndrome, patients receiving t

268 revious serologic diagnosis of HIV, from the acquired immunodeficiency syndrome program of the Health

269 ococcal meningitis accounts for 20 to 25% of acquired immunodeficiency syndrome-related deaths in Afr

270 imately 25% of patients with newly diagnosed acquired immunodeficiency syndrome-related lymphoma (ARL

271 ived a heterologous stem cell transplant for acquired immunodeficiency syndrome-related lymphoma from

272 The outcome of acquired immunodeficiency syndrome-related lymphomas (AR

273 Recent dramatic decreases in acquired immunodeficiency syndrome-related mortality are

274 was used to evaluate the effect of HAART on acquired immunodeficiency syndrome-related mortality, ad

275 Because the incidence of traditional acquired immunodeficiency syndrome-related opportunistic

276 iation between HCV and MI in the Centers for Acquired Immunodeficiency Syndrome Research Network of I

277 n human immunodeficiency virus infection and acquired immunodeficiency syndrome, rheumatoid arthritis

278 lementation has on the progression of simian acquired immunodeficiency syndrome (SAIDS).

279 The mean reporting completeness for acquired immunodeficiency syndrome, sexually transmitted

280 subtyping is not integrated into routine HIV/acquired immunodeficiency syndrome surveillance in the U

281 virus induces a complex disease featuring an acquired immunodeficiency syndrome termed murine AIDS (M

282 aracterized by slower disease progression to acquired immunodeficiency syndrome than results from HIV

283 In acquired immunodeficiency syndrome, the retina is a majo

284 rvum is a major problem in patients with the acquired immunodeficiency syndrome, the specific microbi

285 eficiency virus (HIV) protease inhibitors in acquired immunodeficiency syndrome therapy.

286 interferon era (using data from the European Acquired Immunodeficiency Syndrome Treatment Network [NE

287 the worldwide health problems caused by the acquired immunodeficiency syndrome, tuberculosis, and ma

288 relevance of their epitopes in the design of acquired immunodeficiency syndrome vaccines.

289 tions of measles in the setting of a chronic acquired immunodeficiency syndrome virus infection.

290 eys were used to clarify the distribution of acquired immunodeficiency syndrome virus-specific cytoto

291 The acquired immunodeficiency syndrome was the major cause o

292 age of > 10% and a positive association with acquired immunodeficiency syndrome were borderline signi

293 R, 0.2; 95% CI, 0.03-0.9), but patients with acquired immunodeficiency syndrome were more likely to r

294 eukemia, lymphoma, severe liver disease, and acquired immunodeficiency syndrome were rarely identifie

295 uman immunodeficiency virus infection or the acquired immunodeficiency syndrome, were referred to the

296 ination of brain tissue from 2 patients with acquired immunodeficiency syndrome who had CMV encephali

297 chieving immune restoration in patients with acquired immunodeficiency syndrome who have incomplete r

298 s, malaria, and human immunodeficiency virus/acquired immunodeficiency syndrome, with significant res

299 8 lymphocytes/mm(3)), 90 (18%) progressed to acquired immunodeficiency syndrome within 5 years.

300 st a close friend or intimate partner to the acquired immunodeficiency syndrome within the prior 6 mo